Apexigen IncChange company Symbol lookupSelect an option...APGN Apexigen IncUAVS Ageagle Aerial Systems IncIWSY ImageWare Systems IncAMPX Amprius Technologies IncTNC Tennant CoCVX Chevron CorpACGLO Arch Capital Group LtdAAPL Apple IncBCSF Bain Capital Specialty Finance IncHPE Hewlett Packard Enterprise CoGo
Change company Symbol lookup
Select an option...
APGN Apexigen Inc
UAVS Ageagle Aerial Systems Inc
IWSY ImageWare Systems Inc
AMPX Amprius Technologies Inc
TNC Tennant Co
CVX Chevron Corp
ACGLO Arch Capital Group Ltd
AAPL Apple Inc
BCSF Bain Capital Specialty Finance Inc
HPE Hewlett Packard Enterprise Co
*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
Health Care : Biotechnology |
Company profileApexigen, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents designed to harness the patient’s immune system to combat and eradicate cancer. It has developed a clinical-stage candidate, namely sotigalimab (sotiga or APX005M), which is a humanized agonist antibody. It also has various preclinical and research-stage antibodies it discovered using its APXiMAB platform. It is focused on completing ongoing clinical and manufacturing activities for the sotiga program. The Company’s licensees are advancing five product candidates in clinical development that were enabled by discoveries from its APXiMAB platform. APX005M is under Phase II clinical development for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction cancers and melanoma, in combination with chemotherapy, radiation therapy and immunotherapy.
|
|
|
|
| |
| Latest Earnings Missed Consensus (Q1 ending 03/2023) | Next Earnings Announcement | ||||||
|---|---|---|---|---|---|---|---|
| Q1 Non-GAAP earnings GAAP vs. Non-GAAP EarningsTD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. Announced May 17, 2023 | -$0.25 | Q1 Consensus of 1 analysts | -$0.19 | Difference from consensus | -31.58% | Q2 Earnings will announce | (Unconfirmed) August 14, 2023 |
Quarterly Earnings History and Estimates
Hide high-low estimates
Draw trendlines
Draw up to 3 lines inside the chart.
APGN's fiscal year ends in December
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.
Information provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.